WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Amgen

AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com

Amgen RSS Channel

Filters
List of articles in category Amgen
Title Published Date
Array BioPharma and Amgen Partner in Type 2 Diabetes 16 December 2009
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 05 December 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 06 November 2009
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent 22 October 2009
Denosumab Demonstrates Superiority Over Zometa(R) 22 September 2009
Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product 16 September 2009
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy 26 August 2009
Positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab) 18 August 2009
Studies Highlight Potential New Option in the Treatment of Bone Loss 12 August 2009
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers 05 August 2009
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 28 July 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial 10 July 2009
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure 08 June 2009
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08 24 April 2009
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab 19 February 2009
European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) 07 February 2009
Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients 22 January 2009
Romiplostim Data Show Potential Long-Term Efficacy and Safety 17 June 2008
Amgen Posts Medical Education and Foundation Grants and Donations 27 May 2008
Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12 28 April 2008
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End
Health data interoperability: Opportunities and threats

Business & Industry

  • Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
  • Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
  • Amgen successfully completes acquisition of Five Prime Therapeutics
  • GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
  • Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

Research & Development

  • Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
  • Patients who are obese or overweight are at risk for a more severe course of COVID-19
  • New COVID-19 vaccine may offer broad protection from coronaviruses
  • SARS-CoV-2: New findings on the persistence of neutralizing antibodies
  • Massive fragment screen points way to new SARS-CoV-2 inhibitors
  • B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
  • COVID-19 causes 'unexpected' cellular response in the lungs

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
  • Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
  • AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
  • EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
  1. You are here:  
  2. Home
  3. Amgen
  4. Amgen successfully completes acquisition of Five Prime Therapeutics

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.